ASXL1 and essential thrombocythemia: Although the relationship between ASXL1 mutations and the thrombotic pathogenesis of ET remains unclear, one study suggested that one of the potential strategies to prevent thrombotic events in patients with ET is through blocking the ASXL1 mutations [135].